| abstract |
An agent for inhibiting symmetrical proteins, in particular enzymes, in particular for inhibiting HIV protease, consists of structurally symmetrical or almost symmetrical enzyme inhibitors. The molecules of these enzyme inhibitors have a structure with the same symmetry as the molecule of the enzyme to be inhibited or a structure with partly or approximately the same symmetry as the molecule of enzyme to be inhibited, but in any case with sufficient symmetry to ensure inhibition. |